Healthcare Delivery
Our advocacy promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
EPHA #A2MDialogues
A series of online, live, public dialogues putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe.
Publications
Unleashing meaningful innovation through regulatory reform
Joint position paper on the Pharmaceutical Strategy for Europe
EPHA Position on Medicine Shortages
Latest Developments
On monkeypox vaccines, solidarity, and self-interest
The revision of the EU pharmaceutical legislation: an opportunity to adopt a bold patient-centred set of rules.
The revision of the EU pharmaceutical legislation: balancing between innovation incentives and access to affordable medicines
Public consultation response highlighting critical aspects for the forthcoming revision of the pharmaceutical legislation.
How the Oslo Medicines Initiative can tackle the ever-increasing prices for medicines and vaccines
Speech given by EPHA’s Director General Dr. Milka Sokolović on better access to medicines within the Oslo Medicines Initiative.
Analysis & Opinion
Cancer patients can’t wait any longer for action on access to affordable medicines
The ever-increasing prices of cancer medicines across Europe causes severe threats to patient access and health systems.
After the storm: Lessons, teachings and possibilities of the TRIPS waivers proposal
South Africa and India submitted a proposal to waiver certain dispositions of the Trade- Related aspects of Intellectual Property (TRIPS)
Fairer access to medicines: what needs to change in the revised EU pharma legislation
In the EU there are significant disparities in accessing medicines thus leading to health inequalities across the Union.
